Senior Manager “ Business
Development, Transasia Bio-Medicals Limited
Coagulation remains one of the most important parts of diagnosis in pathology and is routinely suggested as a first line test for disease detection, says Paul Francis Prem, Senior Manager “ Business Development, Transasia Bio-Medicals Limited
The diagnostic segment today comprises a wide array of specialties. With the availability of high-end technologies, it is possible to conduct an in-depth analysis of just about any parameter.
Coagulation remains one of the most important parts of diagnosis in pathology and is routinely suggested as a first line test for disease detection.Ironically, the assay is still restricted to only PT/ATT. uation of even the fibrinogen level (FIB) is considered as a special test. Analysers available in the market offer nothing more than the clot based tests (PT/ ATT) and FIB assays.Moreover, all analysers available in India work on the principle of either mechanical or optical detection.
Mechanical detection is an age old technique based on viscosity. It is an indirect method and is performed with a metal stirrer/bar/bead in the reaction cuvette. The latest direct measurement method is based on the optical scatter light (nephlometry)principle and makes use of clear reagents. This method offers much more information on clot for mationthan its predecessor.
Beyond routine coagulation
Transasia Bio-Medicals has committed itself to offering the latest, highest quality systems across the globe for over thirty five years now.Understanding the customer needs and going beyond limitations to provide the best solutions, has been its forte, earning it credibility globally.
Transasia, along with its subsidiary ERBA Diagnostics, France, has developed a new semi-automated system- ECL series. ECL 105 (single channel analyser) and ECL 412(four channel analyser) are capable of performing all clot, chromogenic and immunotubidometric assays (haemostasis). These systems employ the most advanced and trusted nephlometry principle for detection. The innovative ECL 412 is the only system of its kind to perform the completehaemophilia and thrombophilia panels.The wider test menu provides anedge over all the routine systems. The measurement of clots at 640nm is the first of its kind to measure HIL samples.Moreover, the multi-channel operation son ECL 412 enhances the parallel run of either the duplicate or fresh assays,thereby increasing the throughput.
The system is capable of providing better calibration data for every parameter, resulting in higher accuracy of reporting. The large graphical display aids in viewing the reaction curve for the assay and analysing the data in correlation with the results.
The system uses half the volume of reagents required, thereby making it cost effective with better precision.
Nowadays, most laboratories are accredited and have started using LIS. ECL provides for LIS compatibility and data export system. Vis- -visits counterparts, it offers a wider data storage capacity, an expandable memory and provision for interface and transfer of information.
The system is complimented with a validated, high quality, economic allypriced range of reagents provided by Transasia. By far, the most advanced,the ECL series along with its reagentrange, provide much beyond the clot based assays, offered by all other semi-automated analysers in the market.With its unmatched services, the system is best suited to serve not just standalone labs but corporate hospitals,chain labs and referral labs as well.
All in all, the system offers all test features of a fully automated coagulation analyser on a semi-automated system.
Like
Dislike
Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.
